Company intelligence / Profile preview

Mediar Therapeutics

Cambridge, Massachusetts, USAmediartx.com ↗

Ownership: Private
Employees: ~27
Development stage: Phase 1

Overview

Currently conducting Phase 1 trials for two lead candidates: MTX-463 (targeting WISP1) and MTX-474 (targeting EphrinB2). MTX-463 has received orphan drug and fast track designations from the FDA for IPF. Phase 1 study for MTX-463 is enrolling ahead of schedule with most cohorts dosed as of August 2024, with completion expected by the end of 2024. The company is planning Phase 2 trials in 2025.

Therapeutic areas: PulmonologyRare DiseasesRheumatology
Modalities: Antibodies (monoclonal antibodies)
Industry: Biotech

Drug pipeline

3 assets

MTX-474

2 more assets in the full pipeline.

Request access →

Partnerships

PfizerWuXi BiologicsEli Lilly

Beyond the preview

Go deeper on Mediar Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediar Therapeutics.

Explore the full profile